Qlucore receives European funding as part of consortium project that will benefit Personalized medicine

Hepatitis C patients to benefit from European funding awarded to Qlucore

Qlucore has been awarded funding of €0.6 million over a three year period by the European Commission’s 7th Framework Programme as part of a €6.0 million consortium project (Grant n° 601851) for the development of mathematical and statistical algorithms focusing on integrating data from multiple analytical platforms focusing on integrating genetic and proteomic data with clinical variables. On receiving the award, Carl-Johan Ivarsson, CEO, Qlucore said:

"Personalized medicine, and in particular Hepatitis C patients, will benefit from the project outcome. One of the primary objectives of the consortium is to provide predictive tests that will lead to improvements in the health of these patients, which will simultaneously reduce the costs of medical treatment."